Sandoz launches first generic version of Taclonex® Ointment

Princeton, New Jersey, April 1, 2014 – Sandoz today announced the US market introduction of its calcipotriene and betamethasone dipropionate ointment, the first generic version of Leo Pharma’s Taclonex® Ointment.

​Calcipotriene and betamethasone dipropionate ointment is a vitamin D analogue and corticosteroid combination product indicated for the topical treatment of psoriasis vulgaris in adults 18 years of age and older.

Psoriasis affects approximately 2% of the US population. Plaque psoriasis is the most common form of the condition. [1]

“Sandoz is …

/by

Sandoz launches AirFluSal® Forspiro® in Norway

Holzkirchen, April 2, 2014 – Sandoz announces today that it is launching in Norway AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).

​The product was first approved in Denmark on December 18th, 2013, with subsequent approvals in Germany, Belgium, Sweden, Hungary, Romania and Bulgaria. In February, Sandoz received its first marketing approval in Asia, with marketing authorization in South Korea.

In Norway, Sandoz is launching the 50/250µg and 50/500µg dosage forms for the continuous …

/by

Sandoz launches generic version of PREVPAC® in the US

Princeton, New Jersey, March 27, 2014 – Sandoz today announced the US launch of lansoprazole capsules, amoxicillin capsules, USP, and clarithromycin tablets, USP, a generic version of PREVPAC®1.

​This product is indicated for the eradication of H. pylori infection in patients with duodenal ulcer disease. It comprises amoxicillin and clarithromycin, which are antibiotic medicines, as well as lansoprazole, a proton pump inhibitor that helps decrease production of excess stomach acid2.

“Sandoz is proud to provide a generic version of this …

/by